P-glycoprotein mediates profound resistance to bisantrene

X. P. Zhang, M. K. Ritke, J. C. Yalowich, M. L. Slovak, J. Pelkey Ho, K. I. Collins, T. Annable, R. J. Arceci, F. E. Durr, L. M. Greenberger

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Bisantrene, mitoxantrone, and anthracyclines are anthracene derivatives that interact with DNA and are used for the treatment of cancers. The mechanisms of resistance to bisantrene are unknown. Here we show that cells that overexpress low levels of P-glycoprotein or are transfected with human MDR1 have approximately 10-fold greater resistance to bisantrene compared to vinblastine, doxorubicin, or colchicine. Furthermore, bisantrene can be used to select for high-level P-glycoprotein-mediated multiple drug resistance in a human colon carcinoma cell line, LS 174T, and the drug blocks photoaffinity labeling of P-glycoprotein. The data suggest that bisantrene is an excellent substrate for P-glycoprotein. These findings could influence subsequent clinical evaluation of bisantrene for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)291-301
Number of pages11
JournalOncology Research
Issue number7
StatePublished - 1994
Externally publishedYes


  • P-glycoprotein
  • bisantrene
  • multidrug resistance
  • topoisomerase

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'P-glycoprotein mediates profound resistance to bisantrene'. Together they form a unique fingerprint.

Cite this